^Global Burden of Disease Study 2013, Collaborators (22 August 2015). “Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.”. Lancet (London, England)386 (9995): 743-800. PMID26063472.
^GBD 2013 Mortality and Causes of Death, Collaborators (10 January 2015). “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.”. Lancet (London, England)385 (9963): 117-71. PMID25530442.
^Canellos GP (1992). “Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.”. N Engl J Med.327 (21): 1478-84. PMID1383821.
^Nogová L (2005). “Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).”. Ann Oncol.16 (10): 1683-1687. PMID16093276.
^Diehl V (1999). “Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.”. J Clin Oncol.17 (3): 776-83. PMID10071266.
^Aparicio J (1999). “ESHAP is an active regimen for relapsing Hodgkin's disease.”. Ann Oncol.10 (5): 593-5. PMID10416011.